{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030110","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.428445+00:00","generated_at":"2026-05-17T05:20:35.937827+00:00","sec_items":["1.01","5.02","9.01","2.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025","bullets":["Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.","Current CEO Michael Brigham to become Special Advisor for at least two months and remain on Board.","Base salary of $450,000, annual bonus up to $400,000, $100,000 signing bonus.","Received inducement stock option for 76,673 shares at $5.90; second grant for up to 85,000 shares.","Options vest over three years; options granted Sep 16, 2025 have 10-year term."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030110","json":"https://secwatch.observer/filing/0001437749-25-030110.json","markdown":"https://secwatch.observer/filing/0001437749-25-030110.md","text":"https://secwatch.observer/filing/0001437749-25-030110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774925030110/0001437749-25-030110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774925030110/iccc20250827_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:20:35.937827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}